Monthly Reports

July 2025 Monthly Report

Derek Robinson

• 11 min read
July 2025 Monthly Report

In this blog post, we discuss our July 2025 report and provide more information on how to interpret the results. The PDF report can be found at the end.

Key findings:

  • The median fentanyl concentration found across all drug categories was 7.2%
  • The median fluorofentanyl concentration found across all drug categories was 6.4%
  • The median ortho-methyl fentanyl concentration found across all drug categories was 2.2%
  • Benzodiazepines were found in 41.5% (103/248) of expected Opioid - Down samples
    • Bromazolam was found in 74 Opioid - Down samples with a median concentration of 3.4% and maximum concentration of over 50%
  • Carfentanil was found in 20 Opioid - Down samples with a median concentration of 0.1% and a maximum concentration of 0.5%
  • Xylazine was found in 4 expected Opioid - Down samples with a median concentration of 0.4% and a maximum concentration of 2.4%
  • Medetomidine was found in 12 expected Opioid - Down samples with a median concentration of 1.7% and a maximum concentration of 3.9%

Report Insight

This blog, and the associated pdf report, breakdown our sample counts into six categories:

  • Samples received through direct service provision in Victoria, where service users are bringing samples into the Substance storefront. These samples are labelled as “Substance” samples in the figures/tables of this blog post
  • Samples received through direct service provision in Campbell River, where service users bring samples either to the Vancouver Island Mental Health Society (VIHMS) or Campbell River AVI Health & Community Services. These samples are labelled as “Campbell River”
  • Samples received through direct service provision in the Comox Valley, where service users are bringing samples to AVI Health & Community Services in Courtenay, BC. These samples are labelled as “Comox Valley”
  • Samples received through direct service provision in the Cowichan Valley, where service users bring samples to the Duncan Lookout Society OPS in Duncan, BC. These samples are labelled as “Duncan”
  • Samples received through direct service provision in Port Alberni, where service users bring samples into Port Alberni Shelter Society’s OPS. These samples are labelled as “Port Alberni”
  • Samples received through direct service provision in Port Hardy, where service users bring samples into Island Health Mental Health and Substance Use. These samples are labelled as “Port Hardy”
  • Samples received through indirect service provision, where samples are collected through no-contact drop-off envelopes, are collected by harm reduction workers and other community members at supported housing sites, overdose prevention sites, supervised consumption locations, and the Hospital sample submission kiosks located in Victoria, Nanaimo, and Campbell River. These samples are labelled as “Outreach” samples in the figures/tables herein.

Drug types

Day to day at Substance, we receive and check a wide variety of different samples. Figure 1 shows the prevalence of each expected drug category checked, split by sample collection location/method. Table 1 shows the number of samples received at each sample collection location per expected drug category.

Figure 1. Prevalence of drug classes checked during July split by sample collection/method. Bars are stacked by the percentage of samples in each drug class, with the individual percentages overlaid. Drug classes which represent less than 1% of a given location’s total do not have their percent overlaid onto the bar.
Figure 1. Prevalence of drug classes checked during July split by sample collection/method. Bars are stacked by the percentage of samples in each drug class, with the individual percentages overlaid. Drug classes which represent less than 1% of a given location’s total do not have their percent overlaid onto the bar.
Table 1: Sample counts per location
Table 1: Sample counts per location

The Sample Breakdown

For the majority of samples checked, we confirm the presence of the expected drug with no additional active compounds detected above the limitations of the drug check. The bar charts below highlight a few classes of drugs, differentiating samples where only the expected active component was detected - from situations when other unexpected active components were detected.

Figure 2. Compositional breakdown by drug class and sample collection location/method. Bars are stacked by the percentage of samples in each category, with the relative proportions overlaid. Proportions less than 1% are not overlaid for clarity. “Dark Blue” groups samples that were *as expected* with no other notable compounds detected, “Purple” groups samples that contained the expected drug and contained other unexpected active(s), “Magenta” groups samples that did not contain the expected active but did contain unexpected active(s), “Salmon” groups samples where we were unable to determine the composition (e.g. scenarios where we do not have appropriate reference spectra), and “Lime” displays samples where no active compounds were detected.
Figure 2. Compositional breakdown by drug class and sample collection location/method. Bars are stacked by the percentage of samples in each category, with the relative proportions overlaid. Proportions less than 1% are not overlaid for clarity. “Dark Blue” groups samples that were *as expected* with no other notable compounds detected, “Purple” groups samples that contained the expected drug and contained other unexpected active(s), “Magenta” groups samples that did not contain the expected active but did contain unexpected active(s), “Salmon” groups samples where we were unable to determine the composition (e.g. scenarios where we do not have appropriate reference spectra), and “Lime” displays samples where no active compounds were detected.

Dissociatives

83.8% (67/80) of expected Dissociatives samples were as expected

The remaining samples are as follows:

  • 4 expected methoxpropamine samples also contained 3-HO-PCE and Ondansetron
  • 2 expected methoxpropamine samples also contained 3-HO-PCE
  • 1 expected methoxpropamine sample was 3-HO-PCE and desmetramadol
  • 1 expected fluorexetamine sample was 2F-NENDCK and O-PCE instead
  • 1 expected 2F-NENDCK sample also contained O-PCE
  • 1 expected ketamine sample was cocaine instead
  • 1 expected ketamine sample was methamphetamine instead
  • 1 expected ketamine sample also contained 4-FA and MDMA
  • 1 expected ketamine sample did not have any actives detected

Cocaine

94.0% (110/117) of expected Cocaine samples were as expected

The remaining samples are as follows:

  • 2 expected cocaine sample were ketamine instead
  • 2 expected crack samples also contained phenacetin
  • 1 expected cocaine sample also contained benzocaine
  • 1 expected cocaine sample also contained levamisole and procaine
  • 1 expected cocaine sample did not have any actives detected

Methamphetamine

95.7% (22/23) of expected Methamphetamine samples were as expected

The remaining samples are as follows:
1 expected methamphetamine sample was ketamine instead

MDMA/MDA

91.2% (104/114) of expected MDMA/MDA samples were as expected

The remaining samples are as follows:

  • 3 expected MDMA samples were MDA instead
  • 1 expected MDA sample was MDMA instead
  • 1 expected MDMA sample was ketamine instead
  • 1 expected MDMA sample was bromazolam and fentanyl instead
  • 1 expected MDMA sample also contained tadalafil (Cialis)
  • 1 expected MDMA sample also contained an unknown
  • 2 expected MDMA sample did not have any actives detected

Benzodiazepines (n=42)

38.1% (16/42) of the expected benzodiazepine samples checked in July came to our service sites in the form of pressed pills with the following expected and detected compositions:

Table 2. The composition of benzodiazepine pressed pills checked in July. “Expected Composition” describes the benzo expected/reported by the service user, while “Detected Composition” describes the contents we found through the drug check. “Benzodiazepine (unknown type)” refers to samples where the benzo strip test was positive but no benzos were identified with our other instruments. These unknown benzo samples either contain a benzo at very low concentrations and/or novel benzos that are not in our targeted method for the mass spectrometer.
Table 2. The composition of benzodiazepine pressed pills checked in July. “Expected Composition” describes the benzo expected/reported by the service user, while “Detected Composition” describes the contents we found through the drug check. “Benzodiazepine (unknown type)” refers to samples where the benzo strip test was positive but no benzos were identified with our other instruments. These unknown benzo samples either contain a benzo at very low concentrations and/or novel benzos that are not in our targeted method for the mass spectrometer.

Within the remaining 21 samples:

  • 9 expected avizafone samples were avizafone
  • 2 expected alprazolam samples were alprazolam
  • 1 expected alprazolam (Xanax) sample was bromazolam instead
  • 1 expected alprazolam (Xanax) sample was ethylbromazolam instead
  • 1 expected alprazolam (Xanax) sample was diazepam (Valium) instead
  • 1 expected alprazolam (Xanax) sample was flubromazolam and bromazolam instead
  • 1 expected bromazolam sample was bromazolam
  • 1 expected clonazepam (Klonopin) sample was an unknown benzo instead
  • 1 expected ethylbromazolam sample was ethylbromzolam and a fentanyl or an analogue
  • 1 expected etizolam sample was etizolam
  • 1 expected triazolam sample was temazepam instead

The remaining benzodiazepine sample did not have any actives detected

Opioid-positivity in non-opioid-down samples

In July, we checked 493 samples that were not expected to contain fentanyl or other “unexpected” opioids[1]. Since the opioid-down supply is no longer “just heroin” or “just fentanyl” and is instead a complex, potent, and ever-changing polysubstance market containing other synthetic opioids like fluorofentanyl or nitazenes, here we will examine the prevalence of any unexpected opioid, not just fentanyl, detected in non-opioid-down samples.

  1. Specifically, we are excluding samples that were expected to be “opioid-down” or samples that had an “unknown/missing” expected composition. In the case of “opioid-other” samples, e.g. hydromorphone tablets and oxycodone pills, “unexpected opioids” are defined as any opioid that is not the expected opioid. ↩︎

Table 3. Overview of unexpected opioid detections in non-opioid-down samples in July.
Table 3. Overview of unexpected opioid detections in non-opioid-down samples in July.

Examining Table 3, we find that 3 samples tested positive for unexpected opioids in July, representing 0.6% of all non-opioid-down samples checked. These samples were as follows:

Expected Depressant - Other samples:

  • 1 expected xylazine sample also contained an fluorofentanyl and an unknown benzo
  • 1 expected xylazine sample also contained fentanyl or an analogue

Expected Opioid - Other samples:

  • 1 expected hydromorphone (Dilaudid) sample was fluorofentanyl base and bromazolam instead

For expected MDMA samples, please see "The Sample Breakdown" section above.

For expected benzodiazepine samples, please see the "Benzodiazepines" section above.

In July, no unexpected opioids were detected in samples expected to be cocaine, dissociatives, psychedelics, or methamphetamine.

In people’s personal quests for bodily autonomy and informed consumption, there is often evaluation of risk and consequence, but when the consequences can be severe and the risks are unknown or are intentionally exaggerated, these become difficult, if not impossible, conversations to weigh. We believe that drug checking can help provide people with the information needed to evaluate the risks, and provides harm reduction advice to minimize undesired consequences of substance use. These data are not meant to downplay concerns or invalidate past experiences. We recognize the tragic consequences of when fentanyl is found in non-opioid samples and honour the heartbreak that such experiences produce. Instead, we present these data with the intent to combat misinformation and provide an evidence-based context for people to consider when making decisions about substance use. While these numbers reflect what we have seen over the course of the project, these (roughly) 1-in-100 events still occur, so we always encourage folks to get their stuff checked.

Opioid-Down (n=248)

In this section we present results specific to the opioid-down supply, therefore they may differ from the highlighted findings above that are inclusive of all expected drug categories.

  • 26.2% (65/248) of expected opioid-down samples contained fentanyl as the only active opioid
  • 30.6% (76/248) of expected opioid-down sample contained fluorofentanyl as the only active opioid
  • 12 samples contained heroin, of these samples, 11 contained the related alkaloid acetylcodeine and/or acetylmorphine (MAM). In total, this represents 4.8% of all opioid - down samples.
    • 4/12 samples which contained heroin also contained fentanyl or a fentanyl analogue
  • 8.1% (20/248) of expected opioid-down samples contained carfentanil
  • 8.1% (20/248) of expected opioid - down samples contained ortho-methyl fentanyl
  • 41.5% (103/248) of expected opioid-down samples contained a benzodiazepine
  • The most common benzodiazepine in opioid-down samples was bromazolam (74), followed by desalkylgidazepam (21), benzodiazepine (unknown type) (16), and flubromazolam (1)
  • Xylazine was detected in 1.6% (4/248) of opioid-down samples
  • Medetomidine was detected in 4.8% (12/248) of opioid-down samples
  • A nitazene (N-desethyl isotonitazene) was detected in 1 opioid-down sample this month

In July, 58.1% (144/248) of all opioid-down samples checked contained an additional active to the expected fentanyl/heroin. These data are shown in Fig. 3 highlighting the prevalence of benzos, fluorofentanyl, ortho-methyl fentanyl, carfentanil, and xylazine in the down supply.

Figure 3. The percentage of expected opioid-down samples checked between July 2024 and July 2025 that only contained fentanyl/heroin actives (solid dark purple), opioid-down samples with an additional active detected (dot-dashed purple), opioid-down samples that contained a benzodiazepine-related drug (dotted magenta), opioid-down samples that contained fluorofentanyl (dashed pink), opioid-down samples that contained carfentanil (dashed salmon), opioid-down samples that contained ortho-methyl fentanyl (dashed orange), and opioid-down samples that contained xylazine (dashed yellow).
Figure 3. The percentage of expected opioid-down samples checked between July 2024 and July 2025 that only contained fentanyl/heroin actives (solid dark purple), opioid-down samples with an additional active detected (dot-dashed purple), opioid-down samples that contained a benzodiazepine-related drug (dotted magenta), opioid-down samples that contained fluorofentanyl (dashed pink), opioid-down samples that contained carfentanil (dashed salmon), opioid-down samples that contained ortho-methyl fentanyl (dashed orange), and opioid-down samples that contained xylazine (dashed yellow).

Ortho-Methyl fentanyl was found in 8.1% (20/248) of opioid-down samples.

Fluorofentanyl (specifically the HCl salt) was found in 67% (166/248) of opioid-down samples.

Carfentanil was found in 8.1% (20/248) of opioid-down samples.

Benzo-related drugs contribute to a majority of the other additional actives found in expected opioid-down samples, with 41.5% (103/248) of expected opioid-down samples checked containing a benzo-related drug. Bromazolam continues to be the most common benzo seen in the down supply, being detected in 71.8% (74/103) of the benzo-positive opioid-down samples.

Scattered detections of other drugs are still found and can be reviewed in the pdf report at the end of this blog.

Quantification for Expected Opioid-Down[1]

In July, we quantified fentanyl for 152 of the expected opioid-down samples containing fentanyl and found the median concentration to be 7.6%[2]. Though the median is a useful indicator, it doesn’t capture the volatility of fentanyl concentrations present in the opioid supply, as half of fentanyl-positive down samples contained between 3.5% and 16.8% fentanyl, and any one sample might be the lowest strength (0.2%) or the strongest (greater than 50%[^3]). Fluorofentanyl was seen at concentrations ranging from 0.2% to greater than 50% as well, with a median concentration of 6.7%. In July, we quantified ortho-Methyl fentanyl in 20 opioid - down samples at a median concentration of 2.2%, with half of ortho-Methyl fentanyl positive down samples containing between 1.0% and 6.3% ortho-Methyl fentanyl. Bromazolam, the most common benzodiazepine adulterant in down samples, had concentrations ranging from 3.4% to greater than 50% bromazolam, with a median of 3.4%. Finally, medetomidine, a tranquilizer often used in veterinary medicine, was quantified in 12 samples, with concentrations ranging from 0.3% to 3.9%, with a median of 1.7%.

[3]: For samples that contain greater than 50% fentanyl, heroin, fluorofentanyl, or bromazolam by weight, our mass spectrometer is presently unable to reproducibly assign a concentration due to the upper limits of the calibration methods currently adopted.

  1. Not all opioid down samples brought to our service can be quantified. This is primarily due to too limited sample collected for our instruments to report a reliable mass percentage. Nevertheless, qualitative detection is still possible. ↩︎

  2. This number is specific to fentanyl quantified in opioid-down samples. The median concentration listed in the Key Findings at the beginning of this blog (7.2%) is inclusive of all samples checked, across all drug classes and unknown samples, that contained fentanyl. ↩︎

Table 4. Quantification of low-concentration active components in expected opioid-down samples in July 2025.
Table 4. Quantification of low-concentration active components in expected opioid-down samples in July 2025.

The fentanyl and bromazolam concentrations that we quantified in July, across all expected drug categories and service models, are presented in Fig. 4. Small black dots are individual opioid-down samples, the large white dot shows the median concentration, dashed white lines bound half of the quantified samples, and the width of the shaded regions mirrors the number of samples at a given concentration.

Figure 4. Violin plots of fentanyl (top panel) and bromazolam (bottom) positive samples quantified during July across all collection locations/methods.
Figure 4. Violin plots of fentanyl (top panel) and bromazolam (bottom) positive samples quantified during July across all collection locations/methods.

We can also examine the regional variability in the unregulated market. The table below expands on the quantitative data presented above. It focuses only on fentanyl, fluorofentanyl, carfentanil, bromazolam, and xylazine quantified within expected opioid-down samples, separated by collection location/model. Weight percentage is reported; “IQR” is the interquartile range: the range that contains half of the quantified samples.

Table 5. Quantification of low-concentration active components in expected opioid-down samples, split by service models/location, in July 2025. See Table 4 for the overview from all locations. Weight percentage is reported; “IQR” is the interquartile range: the range that contains half of the quantified samples.
Table 5. Quantification of low-concentration active components in expected opioid-down samples, split by service models/location, in July 2025. See Table 4 for the overview from all locations. Weight percentage is reported; “IQR” is the interquartile range: the range that contains half of the quantified samples.
Substance Drug Checking - July 2025 Monthly Report
Substance Drug Checking - July 2025 Monthly Report.pdf
933 KB
download-circle

Check back next month for the August report!

As always, send us feedback at substance@uvic.ca on how we can continue to offer our drug checking results in a useful way. 

Want to be notified when we release these reports? Join our mailing list by clicking the button below. You'll receive updates about when our reports are available directly in your inbox. You can subscribe and unsubscribe from this list at any time.

Join our mailing list